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Abstract: Introduction: Several immune checkpoint inhibitors (CPIs) are under clinical development in
hepatocellular carcinoma (HCC) and the field is advancing rapidly. In this comprehensive review, we
discuss published results and report on ongoing clinical trials. Methods: A literature search was carried
out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were
included as well. The search was updated 5 March 2021. We evaluated studies with monotherapy
CPI’s, combinations of CPI’s and combinations of CPI’s with other treatment modalities separately.
Only studies with at least 10 included patients were considered. Results: We identified 2649 records
published in the English language literature. After review, 29 studies remained, including 12 studies
with preliminary data only. The obtained overall response rate of PD-1/PDL-1 monotherapy in
phase II studies in the second-line setting was 15–20% with disease control in approximately 60%
of patients. The responses were of long duration in a subset of patients. Furthermore, the safety
profiles were manageable. However, a phase III study comparing nivolumab with sorafenib in
the first-line setting and a phase III study evaluating pembrolizumab versus best supportive care
in the second-line setting did not meet their prespecified endpoints. More recently, a phase I/II
study of nivolumab and ipilimumab has resulted in a response rate of approximately 30% with a
median OS of 22 months in the second-line setting. Multiple trials have been initiated to evaluate
CPIs in combination with molecularly targeted drugs, especially anti-angiogenic drugs or local
therapy. A phase III study investigating atezolizumab plus bevacizumab versus sorafenib in the
first-line setting showed significantly increased survival in the combination arm. Conclusions: The
combination of atezolizumab and bevacizumab represents a new standard of care in the first-line
setting for fit patients with preserved liver function. CPIs can produce durable tumor remission and
induce long-standing anti-tumor immunity in a subgroup of patients with advanced HCC. Although
phase III trials of CPI monotherapy have been negative, the combination of PD-1/PD-L1 inhibitors
with other anti-angiogenic drugs, CTLA-4 inhibitors or other modalities may result in new treatment
options for patients with HCC. Research on predictive biomarkers is crucial for further development
of CPIs in HCC.
Keywords: checkpoint inhibitor; immunotherapy; hepatocellular carcinoma; review
1. Introduction
Liver cancer is ranked as the fifth most common cancer in men and the ninth among
women, with approximately 900,000 new cases worldwide in 2020, and liver cancer is
the fourth leading cause of cancer-related deaths [1]. Hepatocellular carcinoma (HCC)
accounts for 85–90% of all primary liver cancer cases [2,3]. HCC is often preceded by years
of chronic inflammation with development of cirrhosis [4,5], mainly related to hepatitis B
virus (HBV), hepatitis C virus (HCV) [3,6], alcohol or fatty liver disease [7–9].
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Standard treatment for early stage HCC includes liver resection, liver transplantation
and ablation (radiofrequency or microwave). Patients with intermediate stage disease
are selected for trans-arterial chemo-embolization (TACE) and radio-embolization [10].
Although early diagnosis and treatment are important, most patients are diagnosed in
advanced stage. Furthermore, patients receiving local therapy for early stage HCC are
at high risk of recurrence [11]. First-line treatment for patients with advanced HCC and
preserved liver function has consisted of the tyrosine kinase inhibitor (TKI) sorafenib, since
the results of the SHARP [12] and Asian-Pacific (AP) [13] trials were published in 2008 and
2009, respectively. Sorafenib targets multiple kinases including vascular endothelial growth
factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and RAF kinases.
Although sorafenib has a positive effect on median overall survival (OS), the absolute
benefit was marginal (2.8 months increase in the SHARP trial and 2.3 months increase in the
AP trial) [12,13]. Since 2017, several other drugs primarily targeting the vascular endothelial
system have become clinically available [14]. The TKI lenvatinib targeting VEGFR1, 2 and
3, as well as fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, PDGFR alpha, c-Kit,
and the RET proto-oncogene was noninferior to sorafenib as first-line treatment [15], and in
the second-line setting, the RESORCE phase III trial evaluating regorafenib, a multikinase
inhibitor that inhibits the activity of VEGFR1, −2, −3, TIE2, PDGFR, FGFR, KIT, RET,
RAF-1, and BRAF receptor tyrosine kinases, as well as the activity of Abl, has shown an
OS of 10.6 months for patients treated with regorafenib versus 7.8 months for patients
receiving placebo in patients who progressed on sorafenib [16]. More recently, cabozantinib
targeting c-MET, VEGFR1, 2 and 3, and AXL has shown increased median OS compared to
placebo (10.2 versus 8.0 months) in the second- or third-line setting [17]. Finally, a modestly
increased median OS was demonstrated in the REACH-2 trial evaluating ramucirumab, a
monoclonal antibody that inhibits ligand activation of VEGFR2, as second-line therapy for
patients with advanced HCC and increased α-fetoprotein concentrations (median OS of
8.5 months versus 7.3 months in the intervention group compared to placebo) [18].
Recent advances in immune checkpoint inhibitors (CPIs) in other cancer types, e.g.,
melanoma and non-small cell lung cancer, have led to a paradigm shift in clinical practice
highlighting their potential. Historically, patients with viral hepatitis and/or cirrhosis
were excluded from clinical trials with CPIs due to fear of autoimmune hepatitis and viral
reactivation. Promising early reports of the effect of CPIs targeting PD-1 in HCC with
manageable toxicity paved the way for several large studies of CPIs alone or in combination
with other drugs, including randomized clinical trials. Currently, several CPIs have either
been approved or are under development. In this study, we provide an update of results of
clinical studies with CPIs in HCC.
1.1. The Biology of Checkpoint Blockade
Under normal physiologic conditions, a plethora of suppressive pathways in the
immune system exist to maintain inflammatory homeostasis, protect tissue integrity and
protect against unwanted autoimmunity [19]. Tumors exploit these pathways, escaping
immune detection and elimination [20]. The pathways are highly regulated by immune
checkpoints. The two immune checkpoint receptors that have been most studied, cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1),
are both inhibitory receptors acting as brakes on CD3/CD28-dependent signaling. CTLA-4
primarily regulates the amplitude of the early stages of T cell activation. PD-1 signals
through the PD-1 pathway, limiting T cell activation and effector T cell responses. CPIs
in clinical use are antibodies against CTLA-4, PD-1 or its ligand PD-L1. The inhibitors
modulate the interaction between tumor cells and cytotoxic T lymphocytes, whose function
are thought to be exhausted [21]. Targeting CTLA-4 or PD-1/PD-L1 reverses the exhaustion
of cytotoxic T lymphocytes, leading to elimination of tumor cells via re-induction of the
“natural” function of the T cell population [22].
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1.2. Hepatocellular Carcinoma as Target for Immunotherapy
From a clinical standpoint, there is evidence of an activated immune response in
HCC, and by its nature, HCC is a natural target for immunotherapeutic approaches [23]:
reduced infiltration of tumor infiltrating lymphocytes (TIL) in the tumor is correlated with
neoplastic recurrence after liver transplantation [24]; presence of regulatory T cells (tregs)
and cytotoxix T cells (CTL) in tumors has been correlated with patient survival. Thus,
presence of low intratumoral Tregs and high intratumoral CTL has been shown to be a
negative independent prognostic factor for overall survival (OS) [25]; different immune
subtypes of the tumor microenvironment (TME) have been associated with histological
and molecular classification of HCC [26]; and factors such as chronic inflammation [27] and
cirrhosis maintain an immunosuppressive environment and induce T cell exhaustion [28].
Furthermore, immune evasion is a pivotal mechanism in the progression of the disease. It is
beyond the scope of this review to summarize current data. The topic has been excellently
reviewed by others [5,27,29].
2. Materials and Methods
This systematic review was prepared using the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines. We performed a literature search in
PubMed (1966 to 5 March 2021) and Embase (1974 to 5 March 2021). The search string is
available in the Supplementary Material (Search String S1). All searches were restricted to
publications in English. Finally, we searched clinical.trial.gov for ongoing studies.
Retrieved articles and abstracts were included if they met the following criteria:
(1) patients with HCC, (2) prospective clinical trial, (3) treatment with a CPI and (4) data
on efficacy. Ongoing studies with available interim data were included. We excluded case
reports, letters to the editor, reviews, editorials, studies with ≤10 participants and studies
where results could not be extracted separately for HCC.
The screening was performed by two authors (D.L.N. and A.D.-P.) independently. For
relevant records, full text articles were obtained and reviewed for eligibility (D.L.N. and
A.D.-P.). Disagreements in eligibility were discussed until consensus.
The following data were extracted: treatment, phase, number of patients, patient
characteristics (performance status (PS), HCV and HBV infection, Child-Pugh score [30],
Barcelona Clinic Liver Cancer (BCLC) stage [31,32], previous anticancer therapy), outcome
including response rate (RR), duration of response (DOR), disease control rate (DCR),
progression-free survival (PFS) or time to progression (TTP), OS and data concerning
PD-L1 expression. Finally, we extracted overall adverse events (AEs), hepatic-related AEs,
discontinuation rate and number of deaths due to toxicity.
3. Results
Our search identified 2649 records. Seventeen full-text articles and 12 conference
abstracts met our inclusion criteria (Figure 1). A list of CPIs under evaluation in the
treatment of HCC is given in Table 1 and results are summarized in Table 2. Overall toxicity
and hepatotoxicity are given in Table 3.
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Two studies investigated tremelimumab (Table 2). A phase II study [33] evaluated the
drug (15 mg/kg every 90 days; current standard dose [34]) in 21 (17 evaluable) patients
with HCC and chronic HCV infection. Totally, 24% of patients had received sorafenib and
almost half of the patients had comp omised liver function (Child-Pugh B (43%)). Partial
response (PR) was registered in 18%, and 59% of the patients had stable disea e (SD). In 45%
of the p tients, clinical benefit exceeded 6 months. Median TTP was 6.5 months, potentially
biased by long tumor ass ssment intervals (evaluation every 90 days). Median OS was
8.2 months [33]. Notably, tremelimumab in uced a significant decrease in viral load [35].
Tremelimumab at two dose l vels (3.5 and 10 mg/kg every 4 weeks, up to six doses)
followed by 3-month infusions (considered a suboptimal ose) [34] in combination with ra-
diofrequency ablation, cryoablation or TACE was investigated in 32 patients (19 evaluable)
with advanced HCC (Barcelona Clinical liver cancer (BCLC) C 78%) [36]. Sixty percent
had intact liver function (Child-Pugh A), 69% had viral hepatitis and 66% of patients
had received sorafenib. Totally, 26% of the patients experienced PR and 63% had SD,
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which in 45% lasted longer than 6 months. Median TTP and OS were 7.4 and 12.3 months,
respectively [36].
Safety
No immune-related fulminant hepatitis occurred, and no drug discontinuation was
necessary due to hepatitis. However, a transient increase in transaminases ≥ grade 3
was recorded in 45% of patients in the study by Sangro et al. [33], and in the study by
Duffy et al. [36], 9 and 22% of patients experienced grade 3–4 elevations in aspartate
aminotransferase (AST) and alanine aminotransferase (ALT), respectively.
Summary
The abovementioned studies showed an effect of CTLA-4 blockade with tremeli-
mumab in HCC However, the limited sample sizes prevent any formal conclusion on the
magnitude of this effect. The toxicity profile was manageable.
Ongoing Studies
We did not identify ongoing studies investigating monotherapy with CTLA-4 inhibitors.
3.1.2. PD-1/PD-L1 Inhibition; Monotherapy
Nivolumab
The CheckMate 040 study [37] was a phase I/II trial of nivolumab that enrolled
262 patients (BCLC stage C 88% and Child-Pugh A 100%). The trial included patients
with active HBV (24%; dose expansion phase) or HCV (23%; dose expansion phase) in-
fections. Approximately three-fourths of patients had received one prior line of therapy,
usually sorafenib.
In the dose-escalation phase, 48 patients were treated with nivolumab 0.1–10 mg/kg
every 2 weeks in a 3 + 3 design. The RR was 15% with 6% complete responses (CR). Median
DOR was 17.0 months and DCR 58%. Median TTP and median OS were 3.4 months and
15.0 months, respectively.
In the dose expansion phase, the standard dose of nivolumab (3 mg/kg on a 2-week
cycle) was used. In this phase, 20% had a response and SD was reported in 45%. The
DOR was particularly noteworthy as responses lasted for a median of 9.9 months. OS rates
after 6 and 9 months were 83% and 74%, respectively. Median OS was only reached in the
cohort of uninfected patients who had progressed on sorafenib and was assessed to be
13.2 months. Median PFS was 4.0 months.
More recently, preliminary results from the Child-Pugh B cohort in the CheckMate
040 study were presented. Totally, 49 patients, of whom 51% had received prior sorafenib,
received nivolumab. RR was approximate half of RR for Child-Pugh A (10%). However,
the median DOR was comparable to that of Child-Pugh A patients (9.9 months). Median
OS for sorafenib naïve and treated patients was 9.8 and 7.3 months, respectively [38].
In the phase III CheckMate 459 study, 743 patients with advanced HCC were ran-
domized to nivolumab or sorafenib in the first-line setting. At a minimum follow-up
of 22.8 months, the study did not meet the prespecified threshold of statistical signifi-
cance (hazard ratio (HR) 0.84, p = 0.0419). Thus, median OS in the nivolumab arm was
16.4 months versus 14.7 months in the sorafenib arm (HR 0.85, 95% CI 0.72–1.02, p = 0.0752);
the 12-month OS rates were 59.7% with nivolumab and 55.1% with sorafenib and the
24-month OS rates in the two groups were 36.8% and 33.1%, respectively. Median PFS was
similar in the two arms (nivolumab: 3.7. months; sorafenib: 3.8 months), whereas RR was
15% versus 7% (p-values not reported). Patient-reported outcome suggested that patients
receiving nivolumab experienced better quality of life, yet no details were reported [39].
Pembrolizumab
The KEYNOTE-224 phase II study investigated pembrolizumab in 104 patients with
advanced HCC previously treated with sorafenib [40]. Patients had Child-Pugh A and
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approximately half of the patients were HBV (21%) or HCV (25%) positive. Response
was recorded in 17%, and in 77%, the responses lasted for at least 9 months. Forty-four
percent of the patients had SD. Median PFS was 4.9 months and median OS 12.9 months.
Responses were similar in uninfected patients and patients with viral infections [41].
A phase II study of pembrolizumab in advanced HCC including 29 patients, approxi-
mately one-third of whom had previously received sorafenib, showed a RR of 32% with
durable responses (>6 months) in 89% of responding patients. Median PFS was 4.5 months
and median OS 13 months [42].
The KEYNOTE-240 phase III trial investigated pembrolizumab versus placebo plus
best supportive care as second-line therapy [43]. Totally, 278 and 135 patients received
pembrolizumab and placebo, respectively. The patients had Child-Pugh A and 80% had
BCLC stage C. Totally, 26% and 16% were HBV and HCV positive, respectively. RR was
18.3% in the pembrolizumab arm compared to 4.4% in the placebo arm (p = 0.00007). DOR
was durable (13.8 months) in the pembrolizumab arm. DCR was recorded in 62.2% of
patients receiving pembrolizumab compared to 53.3% in the placebo arm. Median PFS was
3.0 months in the pembrolizumab arm compared to 2.8 months in the placebo arm; HR 0.718,
p = 0.022 (pre-specified p = 0.002 required for statistical significance). Pembrolizumab was
found to reduce the risk of death by 22%, and the efficacy was similar across subgroups.
The median OS, however, was 13.9 months in the pembrolizumab arm compared to
10.6 months in the placebo arm; HR 0.78, p = 0.0238 (pre-specified p = 0.002 required for
statistical significance). It has been suggested that subsequent anticancer therapy impacted
the OS results. Thus, 41.7% of patients in the pembrolizumab arm and 47.4% (10.1%
received a PD-1/PD-L1 inhibitor) in the placebo arm received subsequent therapy.
Camrelizumab
A phase II study of camrelizumab included 220 Chinese patients (98% Child-Pugh
A) who were randomized to two different treatment schedules (3 mg/kg every second or
third week). Totally, 83% of patients had HBV infection, and 97% had received previous
treatment. The results were not significantly different between the two regimens. A RR of
14.7%, a PFS of 2.1 months and OS of 13.8 months were recorded [44].
Cemiplimab
The HCC expansion cohort of the phase I study evaluating cemiplimab included
26 patients who all except two had received at least one line of prior therapy. A PR was
seen in 19.2% of patients and 53.8% had SD. Median PFS was 3.7 months [45].
Durvalumab
Durvalumab was evaluated in 40 patients with Child-Pugh A, 93% of which had
received sorafenib. A RR of 10% was shown among all patients. Among HCV-positive
patients, the RR was 25%, whereas no responders were recorded among 23 patients with
HBV-positive disease. The DCR (SD ≥ 24 weeks) among all patients was 33.3%, 62.5% in
HCV-positive patients and 11.1% in HBV-positive patients. The median OS for all patients
was 13.3 months, for HCV positive 19.3 months and for HBV positive 6.3 months [46].
Avelumab
Avelumab was evaluated in a phase II study including 30 patients with Child-Pugh A,
of which 87% had HBV infection and all had received prior sorafenib. PR was recorded
in 10% of patients and DCR was 73%. Median TTP and OS were 4.4 and 14.2 months,
respectively. Thus, the study did not meet its primary end point (RR of 15%) [47].
Safety
Except for a substantial increase in hepatic events, the safety profiles of nivolumab
and pembrolizumab in patients with Child-Pugh A were comparable to that established
for monotherapy in other tumor types [48] (Table 3).
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In patients receiving nivolumab in the dose expansion phase of CheckMate 040,
grade 3–4 AST or ALT increases were reported in 4% and 2%, respectively. Totally, 9%
of patients had AEs leading to discontinuation [37]. In CheckMate 459, the number of
cases with increased liver enzymes was not reported. However, grade 3–4 treatment-
related adverse events (TRAE) were reported in 22% in the nivolumab arm, and 4% of
patients discontinued treatment due to AEs [39]. For patients receiving pembrolizumab in
KEYNOTE-224, increased AST or ALT grade 3–4 was reported in 4% and 2%, respectively,
and immune-related hepatitis was seen in 3%. Five percent discontinued treatment due
to an AE [40]. Additionally, increased AST or ALT grade 3–4 was reported in 13% and
6%, respectively, and hepatitis was seen in 3% of patients in the pembrolizumab arm in
KEYNOTE-240 [43]. No cases of flares of HBV or HCV occurred in these studies.
For patients with Child-Pugh B, 8% had hepatic TRAEs and 4% discontinued treatment
due to TRAEs. Thus, in spite of a numerically higher number of hepatic events, the
discontinuation rate was similar to what has been seen in patients with Child-Pugh A
receiving nivolumab [37,38].
Camrelizumab and cemiplimab had safety profiles similar to other CPIs targeting
PD-1 [44,45]. Except for a high incidence of immune-mediated reactive cutaneous capillary
endothelial proliferation seen in patients receiving camrelizumab (67% compared to <3%
with other PD-1 inhibitors) [44]. Although no grade 3–4 AEs were recorded this finding
might be worrying. Finally, in patients receiving durvalumab or avelumab, no new safety
issues were recorded, grade 3–4 elevated AST/ALT was reported in 13% of patients [46,47].
Summary
PD-1 inhibitors have demonstrated RRs of 15–30%, with durable responses and me-
dian OS of 13–16 months in the first- and second-line setting. However, phase III trials of
nivolumab and pembrolizumab have failed to meet their primary endpoint (OS). PD-L1
inhibitors have only been evaluated in two phase II studies with disappointing RR of
10% and OS of 13–14 months. Except for a substantial increase in hepatic events (increase
in liver enzymes), the safety profiles of PD-1/PD-L1 inhibitors were similar to that for
monotherapy in other tumor types.
Ongoing Studies
We identified 8 ongoing phase I, I/II or III trials evaluating monotherapy with PD-
1/PD-L1 blockade in the advanced setting (Supplementary Table S1). The KEYNOTE-394
trial (NCT03062358) is almost identical to the KEYNOTE-240 trial. However, KEYNOTE-
394 includes patients from Asia and will enroll an estimated 450 patients. Study comple-
tion is expected in June 2021. Also, the PD-1 inhibitor, tislezumab is investigated with
sorafenib as compactor in a phase III study (RATIONALE-301; NCT03412773) using a
non-inferiority design.
3.1.3. PD-1/PD-L1 Inhibition in Combination with Antiangiogenic Agents
HCC is a highly vascularized tumor that exploits angiogenesis to grow and dissemi-
nate [49]. VEGF is one of the key players in angiogenesis and all approved targeted drugs
in HCC inhibit VGEF(R) signaling. By targeting abnormal vessel formation antiangio-
genic agents potentially increase infiltration of immune effectors cells. Thus, combination
of CPI and VEGF(R) targeting therapies may be synergistic and scientific rational [50]
(see discussion).
Pembrolizumab and Lenvatinib
A phase Ib trial of pembrolizumab plus lenvatinib including 100 patients in the
expansion phase has shown a RR of 41% and a DCR of 86%in the first-line setting. The
median DOR was 12.6 months, median PFS was 8.2 months and promising median OS of
22.0 months [51].
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Camrelizumab and Apatinib
Apatinib is a new generation of small molecule anti-angiogenesis inhibitors that
selectively binds to and inhibits VEGFR 2. In addition, this agent mildly inhibits c-Kit and
c-SRC tyrosine kinases. A phase I study of camrelizumab plus apatinib, in patients who
had previously received sorafenib showed a RR of 50% among 16 evaluable patients and a
DCR of 94%. Median PFS was 5.8 months [52]. In addition, a phase II study in the first- and
second-line setting evaluated the combination in 70 and 120 patients, respectively. In the
first-line setting, a RR of 34% and a median PFS of 5.7 months were reported, whereas
RR was 23% and PFS 5.5 months in the second-line setting. OS data were immature with
12-months survival rates of 75 and 68%, respectively [53].
Penpulimab and Anlotinib
Penpulimab is a novel humanized anti-PD-1 IgG1 antibody, which has been engi-
neered to eliminate FC receptor binding activity in order to improve the efficacy [54]. This
drug has been evaluated in patients with advanced HCC in combination with anlotinib,
a multitargeted TKI selective for VEGF receptors 1/2/3, FGF receptors 1–4, PDGF recep-
tors α and β, and c-kit. Totally, 31 patients of whom 77% had BCLC C were included in
the first-line setting. Among 25 evaluable patients a RR of 24% and a DCR of 84% were
reported. Median TTP was not reached, however, 6 months-TTP was 63% [55].
Atezolizumab and Bevacizumab
Recently, data from the HCC cohorts (group A and F) of the phase Ib GO30140 study of
atezolizumab plus bevacizumab were published [56]. In group A all patients received ate-
zolizumab plus bevacizumab. The group included 104 patients with Child-Pugh A, half of
the patients had HBV infection and approximately one-third HCV infection. Totally, 36% of
the patients had a confirmed objective response and 12% obtained CR. The responses were
durable (23% lasting >6 months), and DCR was 71%, median PFS 7.3 months and median
OS 17.1 months [56]. Group F of the same study included 119 patients with Child-Pugh A,
half of the patients had HBV infection and approximately 20% HCV infection. The patients
were randomized to atezolizumab plus bevacizumab vs atezolizumab monotherapy in the
first-line setting. The two arms showed similar RRs (20 vs. 17%), but PFS was significantly
increased in the combination arm (5.6 versus 3.4 months) (HR 0.55, p = 0.011). Thus, PFS
of the combination in group F was shorter than that in group A (7.3 months). However,
this finding may be explained by a shorter follow-up in the F group (median follow up 6.6
vs. 12.4 months). Survival data were immature as median OS was not reached in either
treatment groups [56].
IMbrave150, a phase III study comparing azetolizumab plus bevacizumab with so-
rafenib in the first-line setting, randomized 501 patients with Child-Pugh A. Approximately
half of patients had HBV infection and 20% HCV infection. The RR in the experimental arm
was 29.8% with 7.7% CR vs. 11.3% with 0.6% CR in the sorafenib arm. SD was similar in
the two arms (44.2 vs. 43.4%). A PFS of 6.8 months was observed in the atezolizumab plus
bevacizumab arm vs. 4.3 months in the sorafenib arm (HR 0.59, 0.47–0.76, p < 0.0001), and
median OS was 19.2 months vs 13.4 month (HR, 0.66, 95% CI 0.52–0.85, p = 0.0009) [57,58].
Avelumab and Axitinib
A phase Ib study investigated avelumab plus axitinib in treatment-naïve patients with
HCC. Axitinib is a second generation TKI inhibiting VEGFR 1, 2, and 3, c-KIT and PDGFR.
After inclusion of 22 patients, a RR of 14% and a SD of 68% were observed [59].
Durvalumab and Ramucirumab
The phase Ib study of durvalumab in combination with ramucirumab in patients with
advanced HCC included 28 patients. A RR of 11% and a DCR of 61% were reported. Median
DOR was not reached; however, the lower range was 5.6 months, indicating long-lasting
responses. Median PFS and median OS were 4.4 and 10.7 months, respectively [60].
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Safety
In general, it is reported that the safety profile of the combination therapy was similar
to that reported for the monotherapies [57]. In the study of pembrolizumab plus lenvatinib,
grade 3 and 4 TRAEs occurred in 67% of patients. Overall, 18% discontinued treatment
due to TRAEs and 3% experienced grade 5 events [51]. In the GO30140 study, 68–82%
of patients receiving atezolizumab and bevacizumab (group A and F) experienced any
grade of toxicity and 20% of the patients (group F; TRAE not reported for group A)
had grade 3 to 4 TRAEs, while 41% of patients receiving atezolizumab monotherapy
experienced any grade TRAEs and 5% had grade ≥ 3 toxicity [56]. In Imbrave150, grade
3 and 4 TRAEs were reported in 56.5 and 55.1% of patients in the atezolizumab and
bevacizumab arm and sorafenib arm, respectively. Hypertension was the most frequently
reported TRAE with 15.2 and 12.2 grade 3 to 4 events in the combination and sorafenib arm,
respectively. Approximately 15% in the atezolizumab and bevacizumab arm discontinued
treatment due to AEs. Furthermore, 4.6% (15 patients) in the combination arm died due
to side effects including three patients with gastrointestinal bleeding and two patients
with abnormal liver function and liver injury, respectively [57]. Overall, the incidence
of upper gastrointestinal bleeding in the atezolizumab and bevacizumab arm was 7%
which is similar to other studies of bevacizumab in HCC [61]. The safety profile of the
combination of camrelizumab and apatinib was reported to be similar to that reported
for the monotherapies [52,53]. No AEs ≥ grade 3 were reported in the study of avelumab
and axitinib, and no patients discontinued treatment due to AEs [59]. In the study of
penpulimab plus anlotinib 10% of patients experienced grade 3 TRAE, it was reported that
no unexpected AE were identified [55]. Also, in the study of durvalumab and ramucirumab,
no unexpected toxicities were demonstrated [60]. In general, however, the regimens are
associated with a high incidence of grade 3–4 toxicity (20 to 57%) with hypertension as the
most common side effect counting for 5 to 50% of grade 3–4 events (Table 3).
Summary
In general, combinations of PD-1/PD-L1 inhibitors and VEGF(R) targeting therapy
improved RR, PFS and OS compared with CPI monotherapy in the first-line setting. Most
important, atezolizumab in combination with bevacizumab has shown significantly in-
creased median OS compared to CPI monotherapy. The increased efficacy was obtained at
the cost of a high incidence of grade 3–5 toxicity.
Ongoing Studies
Thirty-eight ongoing studies are investigating dual CPI and antiangiogenic agents, seven
of which are phase III randomized studies. The phase III study (LEAP-002; NCT03713593) of
lenvatinib +/− pembrolizumab will provide data on the efficacy of combination therapy.
Results are expected in July 2022. A phase III study (NCT03764293) compares camre-
lizumab in combination with apatinib with sorafenib monotherapy. Two phase III studies
(COSMIC-312; NCT03755791 and IMbrave251; NCT04770896) evaluate atezolizumab in
combination with different VEGFR inhibitors (lenvatinib, sorafenib and carbozantinib).
Furthermore, sintilimab in combination with the VEGF-antibody, IBI305 is compared to
sorafenib (NCT03794440). Finally, toripalimab is investigated in two studies in combination
with lenvatinib and bevacizumab, respectively (NCT04523493; NCT04723004).
3.1.4. CTLA-4 and PD-1/PD-L1 Inhibition
The combination of CLTLA-4 and PD-1/PD-L1 inhibition has been found to produce
a higher incidence of durable responses across several malignancies, albeit at the expense
of a dose dependent increased rates of immune-related AEs [62].
Nivolumab and Ipilimumab
Recently, results for the combination of nivolumab and ipilimumab in the CheckMate
040 trial (three different dosing regimens) were reported. Totally, 148 patients who had
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previously received sorafenib were included. More than 90% of patients had BCLC stage
C. The RR, DOR and DCR were similar across treatment arms. Overall OR was 31% with
5% CR. DCR was reported to be 49%. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg Q3W
(4 doses) followed by nivolumab 240 mg Q2W was found to have a promising median OS
of 22.8 months, whereas the median OS in the other cohorts was 12.5 and 12.7 months,
respectively [63].
Durvalumab and Tremelimumab
A phase I/II study of durvalumab and tremelimumab included 40 patients, of whom
50% were HBV or HCV positive and 30% had no prior systemic therapy [64]. The RR was
15% in all patients and 30% in uninfected patients. No patients with viral infection had
response. The DCR (SD≥ 16 weeks) was 58% in all patients and 70% in uninfected patients.
Preliminary results from the expansion cohort of the same study included 332 patients
treated in the first-line setting. The patients were randomized to four arms: A single dose
of tremelimumab plus durvalumab, tremelimumab plus durvalumab, and monotherapy
of durvalumab and tremelimumab, respectively. The RR were 22.7, 9.5, 9.6 and 7.2% with
median OS of 18.7, 11.3, 11.7, and 17.1 months. Thus, highest clinical activity was found for
the single dose tremelimumab (priming dose) plus durvalumab regimen [65].
A phase II study of the combination in patients with HCC or biliary cancer reported
preliminary data on 10 patients with HCC. A RR of 50%, a PFS of 7.8 months and a median
OS of 15.9 months were reported [66].
Safety
The combination of nivolumab and ipilimumab resulted in 31–53% 3–4 grade TRAEs,
and 2–18% of patients discontinued treatment due to toxicity [63]. Patients receiving
nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W followed by nivolumab 240 mg Q2W
experienced the highest rates of adverse events, immune-mediated events and discontin-
uation rate due to toxicity. Totally 20% of patients receiving this combination developed
hepatitis. On the other hand, the toxicity was manageable and 90% of hepatic events
resolved using protocol-specified management algorithms.
In the phase I/II study of durvalumab and tremelimumab, the most common grade≥ 3
related AE was asymptomatic increased AST (10%). In all, 7.5% of patients discontinued
treatment due to AEs [64].
Summary
The best performing combination regimen of nivolumab and ipilimumab resulted in
increased RR of 31% with a median OS of 22 months in the second-line setting whereas the
best performing regimen of durvalumab plus tremelimumab showed a RR of 23% and a
median OS of 19 months in the first-line setting. Except for hepatotoxicity, the safety profile
of the combinations was consistent to that found in studies investigating the combination
in other tumor types [67].
Ongoing Studies
Six ongoing studies are investigating the CPI combination strategy. The phase III
CheckMate 9DW (NCT04039607) is scheduled to include 1084 patients randomized to
nivolumab and ipilimumab vs sorafenib or lenvatinib. Results are expected in September
2023. Additionally, sintilimab in combination with the CTLA-4 inhibitor, IBI310 is compared
to sorafenib in a phase III study expected to include 490 patients (NCT04401813). Finally,
a phase III study, HIMALAYA, will compare the efficacy of durvalumab plus single dose
tremelimumab with durvalumab monotherapy vs sorafenib (NCT03298451).
3.1.5. PD-1/PD-L1 Inhibitor in Combination with Chemotherapy
Preliminary data from a phase II study of camrelizumab in combination with FOL-
FOX4 (5-fluorouracil, leucovorin, oxaliplatin) or GEMOX (gemcitabine, oxaliplatin) in
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patients with advanced HCC or biliary tract cancer showed a RR of 27% among 27 patients
with HCC and a DCR of 79%. The median PFS was 5.5 months. Notably, 85% of patients
experienced grade 3–4 toxicity [68].
3.1.6. PD-1/PD-L1 Inhibitor in Combination with Local Therapy
Efficacy
A proof-of-concept study enrolled 50 patients with advanced HCC (74 extrahepatic
metastases), who had previously received or had unacceptable toxicity of sorafenib [69].
Thirty-three of the patients with stable disease or mixed response to single agent PD-
1 inhibitor (nivolumab or pembrolizumab) received subtotal thermal ablation. Among
50 patients treated with PD-1 inhibitor 10% of patients had a response and 42% SD. Ad-
ditional ablation increased RR to 24%. Median PFS for all patients was 5 months and OS
16.9 months [69]. The combination of Y90-radioembolization and nivolumab has been
investigated in a study of 40 patients with advanced HCC of which 64% had BCLC C and
14% had received prior systemic therapy. The study showed an encouraging RR of 31%.
PFS and OS were 4.6 months and 15.1 months, respectively [70].
Safety
The combination of CPI with local therapy seems well tolerated, with no new safety
issues [69,70].
Summary
Two small studies indicate that local therapy might increase the efficacy of CPI,
however, the limited sample sizes of the studies prevent any formal conclusion on the
efficacy of this combination.
Ongoing Studies
A range of phase I and phase II trials are investigating different CPIs in combination
with other agents or other treatment strategies, but we identified only two phase III studies.
In a phase III study, camrelizumab plus FOLFOX is compared to FOLFOX or sorafenib
(NCT03605706). Furthermore, a phase III study is planned to compare toripalimab in
combination with radiotherapy to sorafenib in patients with HCC, BCLC stage C and
portal vein thrombosis (NCT04709380).
3.2. Locally Advanced Setting
No results were reported. Twenty-five studies including three phase III studies are
ongoing in this setting combining CPI with Y90 microspheres (SIRT), ablation or transar-
terial chemoembolization (TACE) (Supplementary Table S2). Most interesting, a placebo-
controlled phase III study expected to include 765 patients compares nivolumab with and
without ipilimumab in combination with TACE to TACE alone (NCT04340193). Addition-
ally, a placebo-controlled phase III study is investigating chemoembolization in combina-
tion with durvalumab or durvalumab plus bevacizumab (EMERALD-1; NCT03778957).
Finally, a phase III study is evaluating atezolizumab plus bevacizumab in combination
with TACE with TACE alone (NCT04712643).
3.3. Preoperative and Adjuvant Setting
3.3.1. Efficacy and Safety
The phase II randomized study of nivolumab vs nivolumab plus ipilimumab as
preoperative therapy in 27 patients with resectable HCC reported a pathological complete
response (pCR) rate of 24% among 21 patients who proceeded to surgery (surgery was
aborted in 6 patients including 3 patients with progressive disease). Furthermore, 16%
had major pathological responses. Among all randomized patients the pCR rate was 19%
(preliminary data). Totally, 5% and 24% of the patients experienced grade 3 toxicity. Surgery
was not delayed or cancelled due to toxicity [71].
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3.3.2. Ongoing Studies
We identified ten ongoing studies including two ongoing randomized phase II studies
(NCT03510871; NCT03222076) in the neoadjuvant setting. In the adjuvant setting, thir-
teen trials were identified (two were also neoadjuvant) including seven phase III trials
(Supplementary Table S3).
Importantly, three phase III studies evaluating monotherapy with nivolumab (Check-
Mate 9DX; NCT03383458), pembrolizumab (KEYNOTE-937; NCT03867084), and toripal-
imab (NCT03859128), respectively, as adjuvant therapy after curative resection or ablation
are in progress. The studies will each include 530, 950 and 402 patients and are expected
to be completed in 2022, 2025, and 2022 respectively. Three studies are investigating the
combination of CPI and VEGF(R) inhibitor: NCT04682210 (sintilimab + bevacizumab vs.
active surveillance), NCT04639180 (camrelizumab plus apatinib vs. active surveillance)
and NCT04102098 (IMBrave 050; atezolizumab in combination with bevacizumab vs. ac-
tive surveillance). Each study is planned to include 246, 674 and 662 patients and to be
completed in 2023, 2024 and 2023, respectively. Furthermore, a fourth study investigating
durvalumab alone and in combination with bevacizumab (EMERALD-2) in the same set-
ting is underway. This study is expected to include 888 patients and to be completed in
June 2022.
3.4. Biomarkers
PD-L1 expression level was investigated in eight studies with divergent results
(Table 4) [37,39–42,44,52,60]. In three studies, only 14–50% of the samples were avail-
able [40,42,44], and one study included tumor types other than HCC [52]. Furthermore,
in most studies no statistical analyses were performed. In CheckMate 40, 81% of the
patients in the dose-expansion phase were investigated. PD-L1 ≥ 1% on tumor cells was
expressed in 20% of assessed tumors and in 26% (95% confidence interval (CI) 13–44%) of
tumors with objective response. No correlation was reported [37]. In contrast, evaluation
of PD-L1 in CheckMate 459 showed a higher RR in PD-L1-positive patients receiving
nivolumab (PD-L1 ≥ 1% RR 20/71 (28%); PD-L1 < 1% RR 36/295 (12%)) (no p-values were
reported) [39].
In Keynote-224, a retrospective analysis of PD-L1 expression with available data (half
of the patients) revealed that PD-L1 expression assessed by a combined positive score
(CPS) (a measure of PD-L1 positive immune and tumor cell number) was associated with
response. In contrast, the tumor positive score (TPS) did not correlate with response [40,41].
In the study of camrelizumab, PD-L1 expression data were only available in 30 of
220 patients. The RR was reported in 36% of 11 patients with PD-L1 ≥ 1% and in 11%
of 19 patients with PD-L1 < 1% [44]. No responses were reported among 15 patients
with low expression of PD-L1 on circulating tumor cells in the study of camrelizumab
and apatinib [52]. In contrast, objective responses were observed irrespectively of PD-L1
expression in the GO30140 study. Furthermore, patients with PD-L1 positive tumors seem
to have the shortest PFS. However, evaluating the association between PD-L1 and efficacy
was challenging due to small numbers of patients in some of the subgroups [56]. Finally,
response rates and median OS were comparable regardless of PD-L1 expression in the
nivolumab plus ipilimumab part of CheckMate 040 [63]. In the study of camrelizumab and
apatinib [52], patients with PR/SD at first response evaluation showed significantly higher
TMB than those with PD (mean 8.53 vs. 1.44 mutations/MB; p = 0.0002); however, PFS was
not significantly different (p = 0.063).
4. Discussion
The promising results of early studies with PD-1 monotherapy in HCC generated
much enthusiasm [37,40]. In 2017 and 2018 FDA granted accelerated approval to nivolumab
and pembrolizumab, respectively, for second-line therapy in advanced HCC. Nonetheless,
the KEYNOTE-240 trial investigating pembrolizumab vs placebo plus best supportive
care in the second-line setting did not meet its coprimary endpoints [43]. Furthermore,
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the phase III CheckMate-459 head-to-head trial of nivolumab vs sorafenib in the first-
line setting did not meet its pre-specified primary outcome (OS) [39]. Anyhow, a high
frequency of subsequent use of systemic therapy including immunotherapy in the sorafenib
arm might have blurred the results. Recently (11 March 2021), FDA announced that the
agency would discuss (27–29 April 2021) indications granted with accelerated approval for
pembrolizumab, atezolizumab, and nivolumab [72].
Whereas, nivolumab and pembrolizumab have partly overlapping binding epitopes
camrelizumab has been found to interact with a unique epitope of the PD-1 molecule [73].
However, results regarding monotherapy with camrelizumab are similar to those of
nivolumab and pembrolizumab.
Taken together, current results on CPI monotherapy are unlikely to change the stan-
dard of care in treatment of HCC, primarily due to lack of reliable predictive factors.
Although all studies have shown relatively high response rates and durable responses, at
least 30% of patients have unequivocal progression on CPI monotherapy and all patients
progress at some point. Therefore, development strategies to improve outcomes have
become urgent. The strategies have frequently been based on drug combinations that
include drugs targeting the vascular endothelial system, including drugs already proven
efficient in HCC (sorafenib, lenvatinib, regorafenib, ramucirumab and cabozantinib).
Several factors constitute the rationale for combination of CPIs targeting PD-1/PD-L1
and antiangiogenic agents: VEGF(R) inhibition promotes maturation of dendritic cells and
modulates multiple effectors including cytotoxic and regulatory T cells and natural killer
cells resulting in an effective priming and activation of T cells [74,75]; the combination
anti-PD-1/PD-1 and antiangiogenic therapy normalizes vessel formation and promotes
infiltration of T cells into the tumor [76,77]; antiangiogenic therapy inhibits the activity
of immunosuppressive cells (regulatory T cells (tregs), tumor associated macrophages
(TAMs) and myeloid-derived suppressor cells (MDSCs)) changing an immunosuppres-
sive microenvironment to an immunostimulatory environment [78]; and anti-PD1/PD-L1
therapy enhances the ability of T cells to attack tumor cells [76,77].
Several studies have shown impressive response rates, durable responses and favor-
able PFS using the combination of a CPI targeting PD-1/PD-L1 and VEGF(R) inhibition.
Recently, data from the HCC cohorts (group A and F) of the phase Ib GO30140 study of ate-
zolizumab plus bevacizumab were published [56]. In group F patients were randomized to
atezolizumab plus bevacizumab vs atezolizumab monotherapy in the first-line setting. The
two arms showed similar RR, however, PFS was significantly increased in the combination
arm (5.6 vs. 3.4 months). Furthermore, results from the IMbrave150 study comparing the
combination of azetolizumab and bevacizumab with sorafenib in the first-line setting have
shown significant improvements in PFS and median OS in the experimental arm. The
combination was approved of FDA in 2020 and results have been groundbreaking changing
standard of care in the first-line setting. Although, the toxicity reported was not trivial,
with 57% grade 3 or 4 AEs [57], guidelines from e.g., ASCO recommend atezolizumab plus
bevacizumab to be offered to most patients in the first-line setting [79].
In addition, a phase Ib trial of pembrolizumab plus lenvatinib have showed a RR
of 41% in the first-line setting. Median PFS was 8.2 months and OS 22.0 months [51].
Although clinically meaningful efficacy was achieved in this study, the combination is not
approved by the US Food and Drug Administration (FDA) as the “application request
did not show sufficient evidence that the pembrolizumab plus lenvatinib combination
represented a “meaningful advantage” over already available therapies” [80].
Although results concerning combination therapy with anti-PD-L1/PD1 inhibitors
and angiogenenic therapy have been impressive, some crucial issues persist, such as
validation in Western patients, because they present a different molecular profile of HCC
(75% of patients in GO3014 were Asian and 40% of patients were Asian (excluding Japan)).
Another consideration may be safety in unselected patients. Hence, the effect of TKIs may
be dose and agent dependent [81]. Preclinical studies have shown that lower doses of TKIs
were superior to higher doses in inducing homogeneous tumor vessel normalization [82].
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The use of lower, vascular-normalizing doses of anti-VEGF therapies is supported by
emerging clinical data in other tumor types [83] but needs further confirmation in studies
in HCC.
The PD-1/PD-L1 and CTLA-4 pathways have distinct but complementary roles in
negatively regulating immune activity (see “Section 1.1”). Thus, it seems biologically ratio-
nal to combine inhibitors of the two pathways. Nivolumab plus ipilimumab has proved
effective in the treatment of other tumor types [84,85]. Few studies have investigated the
combination of a PD-1/PD-L1 inhibitor and a CTLA4 inhibitor in HCC. Most important, the
combination of nivolumab and ipilimumab in the CheckMate 040 trial provided a robust
clinical benefit [63]. Patients in the combination arm with the highest dose of ipilimumab
had the highest CR rate and the most promising median overall survival (22.8 months).
These results suggest that an increased dose of ipilimumab may translate into higher rates
of durable responses and improved survival in patients with HCC. Similar results have
been reported for other tumor types e.g., melanoma, renal cell carcinoma [86,87]. This
combination was approved by FDA for HCC in 2020.
More recently, a systematic review including eight studies (6290 patients) in the first-
line setting and six (2653 patients) in the second-line has been published. In the first-line
setting, network meta-analysis showed the combination of atezolizumab and bevacizumab
was superior compared with lenvatinib (HR 0.63, 95% CI 0.44–0.89), sorafenib (HR 0.58,
95% CI 0.42–0.80), and nivolumab (HR 0.68, 95% CI 0.48–0.98) with regard to OS. In the
second-line setting, the analyses showed that all studied drugs had a PFS benefit compared
with placebo. However, this only translated into OS benefit with regorafenib, cabozantinib
and ramucirumab compared with placebo [88].
A different approach to improve the response is to modulate the immunogenicity of
tumors or to boost the immune system by combination of locoregional and/or radiotherapy
with immunotherapy. Thus, local therapy, such as radiofrequency ablation, TACE, SIRT or
radiotherapy, may promote an immune response via the influence of the TME [89–91]. This
approach is based on releasing tumor antigens through cell death induced by locoregional
therapy, which subsequently improves immunotherapy due to better antigen presentation.
A single, small, unrandomized study evaluating subtotal thermal ablation in combination
with PD-1 inhibition in patients with advanced disease has shown an increased response
rate after ablation supporting this treatment strategy [69]. This leaves a hypothetical role
for CPI given in a combination with local treatment. Several open questions remain to be
answered regarding patient selection, optimal timing and sequence of therapies and choice
of combination. It will take several years before mature survival data become available [92].
Furthermore, translational studies are also needed to improve the understanding of the
exact molecular mechanisms involved in the response or failure of these combinations.
We identified a huge number of ongoing studies, but only a few randomized, poten-
tially practice-changing studies were identified. The scientific rationale behind parallel
testing of multiple drugs in different combinations may be questioned. There is a need for
rational/coordinated development of immunotherapy across the heterogeneous treatment
landscape. On the other hand, the many generic drugs developed for the same indication
will definitely increase competition and probably result in lower prices.
4.1. Biomarkers
Among the most investigated predictive biomarkers for CPI blockade are PD-L1,
microsatellite instability/defective mismatch repair (MSI/dMMR) and tumor mutational
burden (TMB). CPI is approved for clinical use in tumors with MSI/dMMR irrespective
of tumor type, however, in two large series (122 patients and 82), the incidence of MSI in
HCC was very low (0 and 2.4%) [93,94]. TMB representing genomic instability is emerging
as a potential predictor of response to immunotherapy [95,96]. In general, only a few HCC
tumors are TMB high [97]. TMB has only been reported in one study [52]. Therefore, the
value in HCC is unclear.
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PD-L1 expression on tumor cells predicts efficacy of PD-1/PD-L1 inhibitors in several
tumor types. More recently, guidelines for implementation and interpretation of PD-L1
expression has been published [98]. However, the value of PD-L1 as the “definitive”
biomarker is controversial [99,100]. Regarding testing, many unsolved issues exist includ-
ing the use of different staining platforms and antibodies, the type of cells in which PD-L1
is assessed and thresholds for PD-L1-positivity.
Limited data on PD-L1 expression in HCC have been reported. Not surprisingly,
hepatocytes and Kupffer cells have been found to express high levels of PD-L1 [101–104].
However, a significant inter-assay discordance in the quantitation of PD-L1 level in HCC
has been reported [105]. Additionally, a significant heterogeneity was found in PD-L1
expression in the KEYNOTE-224 study [40,41]. In all reported studies, clinically meaningful
responses were observed in patients with PD-L1 expression < 1% (Table 4). Anyhow,
patients with a high PD-L1 expression had a numerically increased response rate in the
CheckMate 040 study and PD-L1 expression was associated with improved OS (median
28.1 vs. 16.6 months) [106]. In addition, patients with a high PD-L1 expression had a
numerically increased response rate in the CheckMate 459 study, suggesting that the
marker might be reliable in HCC [39]. Taken together, there might be an association of
PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy in HCC and PD-
L1 expression might be a valuable predictor of the efficacy of anti-PD-1/PD-L1 therapy
in certain patients, however, analyses from especially combination studies showed that
patients benefited from immunotherapy regardless of PD-L1 expression level.
The immune response, however, is the result of multiple factors including the antigenic
characteristics of the tumor and the multiplicity and phenotypes of tumor-associated antigen-
specific cytotoxic T lymphocytes. From this perspective, the use of a single biomarker seems
insufficient [107]. Several other candidate biomarkers have been suggested including
tumor infiltrating lymphocytes, CD8 + T cell density in the TME, IFNγ signaling, Wnt/β-
catenin signaling and genetic signatures [108,109]. More recently, Sangro et al. found an
inflammatory gene signature consisting of four genes to be associated with RR (p = 0.05)
and OS (p = 0.01) in CheckMate 040 (37 of 262 patients included in analysis). The findings
have not been validated [106].
Even though several serum biomarkers have been suggested and liquid biopsy is
emerging as a clinical tool [110,111], there are currently no validated predictive biomarkers
able to guide treatment choice and identification of predictors of response represents a
major challenge [112]. Furthermore, the routine clinical practice of largely abandoning
histological confirmation of the diagnosis in favor of radiologic criteria [113] is in conflict
with a future perspective integrating biomarker information for therapeutic stratification
of patients with HCC.
4.2. Patient Selection
With a few exceptions CPI is or has been investigated in patients with HCC Child-
Pugh A. Preliminary results from the Child-Pugh B (7 + 8) cohort of the CheckMate
040 study investigating nivolumab showed an RR (10%) of approximate half of RR for
Child-Pugh A patients. Furthermore, an increased number of hepatic adverse events were
demonstrated in the Child-Pugh B cohort [38]. A retrospective study including 132 and
71 patients classified as Child-Pugh A and B, respectively, found a lower RR (2.8% vs.
15.9%, p = 0.010) and shorter OS (11.3 weeks vs 42.9 weeks, p < 0.020) for patients with
Child-Pugh B compared to patients with Child-Pugh A [114]. Additionally, a systematic
review of 597 patients with HCC found a significant correlation between number of grade
≥3 AEs and the proportion of patients with Child-Pugh B [115]. Although toxicity was
manageable and the discontinuation rate was similar for Child Pugh A and B patients in
ChechMate 040, these findings indicate that CPI should not be used in unselected patients
with Child-Pugh stage B.
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4.3. Safety
Although cirrhosis was present in >80% of the patients, the early fear of immune-
mediated hepatitis did not pan out. Brown et al. performed a literature review on monother-
apy ipilimumab, tremelimumab, nivolumab or pembrolizumab for patients with HCC,
melanoma and non-SCLC [48]. Although, the study showed a substantial increase in
hepatic events in patients with HCC as compared to patients with melanoma or non-SCLC,
there was no significant difference among the groups with respect to treatment discontinu-
ation or deaths secondary to drug toxicity. Another concern has been hepatitis B and C
reactivation. A systematic review found a very low degree of virus activation. However,
the authors recommend patients with active viral hepatitis to be monitored closely and
treated with antiviral therapy if indicated [116].
Patients receiving a combination CPI and VEGF(R) inhibitor experienced a high
number of grade 3–4 TRAE (Table 3). However, in the IMbrave150 study AE grade 3 to
5 TRAEs tended to occur at same rate in the sorafenib arm and the atezolizumab plus
bevacizumab arm [57]. In addition, findings from a systematic review of pembrolizumab
plus lenvatinib vs. pembrolizumab and lenvatinib monotherapies in a range of different
cancer types has indicated that the combination did not increase drug toxicities and that
the toxicity profile was manageable [117].
The safety profile of combination therapy with nivolumab and ipilimumab was consis-
tent with studies investigating the combination in other tumor types [67]. Anyhow, ASCO
guidelines underscore the risk of life-threatening toxicity [79].
Finally, a systematic review and a pooled analysis of 2403 patients with unresectable
HCC receiving CPIs concluded that CPIs are safe. However, among 15 patients who
received CPI in the setting of liver transplant, fatal graft rejection was reported in 40% and
the mortality rate was 80%. Thus, the authors warranted caution regarding use of CPI in
this setting [118].
5. Conclusions
The combination of atezolizumab and bevacizumab has resulted in a paradigm shift in
the treatment of HCC and has changed practice in first-line setting. CPIs have the potential
to produce durable tumor remission and induce long-standing anti-tumor immunity
in a subgroup of patients with HCC. Results of CPIs in localized HCC in combination
with local therapies and as neoadjuvant or adjuvant therapy in resectable disease are
awaited. Research for predictive biomarkers is crucial for further development of this
treatment modality.
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Table 1. Immune checkpoint inhibitors under evaluation in clinical trials in hepatocellular carcinoma.
Compound Company IgG Class
CTLA-4 inhibitor
Ipilimumab, Yervoy® (BMS-734016) Bristol-Meyers Squibb (New York, NY, USA) IgG1, fully human
Tremelimumab (MEDI1123, formerly known
as ticilimumab)
MedImmune (Gaithersburg, MD, USA)/




Bristol-Meyers Squibb (New York, NY, USA) IgG4, fully human
Pembrolizumab, Keytruda® (MK-3475,
lambrolizumab)
Merck (MSD) (Kenilworth, NJ, USA) IgG4, humanized
Tislelizumab (BGB-A317) BeiGene Boehringer Ingelheim IgG4, humanized
Camrelizumab (SHR-1210) Jiangsu HengRui (Lianyungang, China)/Incyte(Wilmington, DE, USA) IgG4, humanized
Cemiplimab, Libtayo® (REGN2810)
Regeneron (Tarrytown, NY, USA)/Sanofi
Genzyme (Cambridge, MA, USA) IgG4, fully human
Spartalizumab (PDR001) Novartis (Basel, Switzerland) IgG4, humanized
Sintilimab, Tyvyt® (IBI308)
Innovent Biologics (Suzhou, China)/Eli Lilly
(Indianapolis, IN, USA) IgG4, fully human
Toripalimab (JS001) Shanghai Junshi Biosciences (Shanghai, China) IgG4, humanized
Penpulimab (AK105) Akeso Biopharma (Zhongshan, Anhui, China) IgG1, humanized
PD-L1 inhibitor
Atezolizumab, Tecentriq®, MPDL3280A
Genentech (South San Fransico, CA,
USA)/Roche (Basel, Switzerland) IgG1, fully humanized
Durvalumab, Imfinzi®, (MEDI4736)
MedImmune (Gaithersburg, MD,
USA)/AstraZeneca (Cambridge, UK) IgG1, fully human
Avelumab, Bavencio®, (MSB0010718C)
Merck Serono (Darmstadt, Germany)/Pfizer
(New York, NY, USA) IgG1, fully human
Lodapolimab (LY3300054) Eli Lilly (Indianapolis, IN, USA) IgG1, fully human
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Advanced, not amenable for resection or ablation
CTLA-4 inhibition





















Duffy [36] Tremelimumab +
RFA/CA/TACE





only; n = 19)
TTP 7.4 (4.7–19.4)
















DCR 89Extrahepatic disease 44

































































Child-Pugh B7–8 DCR 55.1
Vascular invasion or





data) 371 vs. 372




RR 15 (CR 4) vs.
3.7 (3.1–3.9) vs. 3.8
(3.7–4.5)
16.4 (13.9–18.4) vs. 14.7
(11.9–17.2)7 (CR 1)
Sorafenib
PS 0–1 SD 35 vs. 48
HR 0.85 (0.72–1.02);
p = 0.0752Child-Pugh A
DOR 23.3 months
(3.1–34.5 +) vs. 23.4
months (1.9–28.7 +)














(Keynote-224) Pembrolizumab II 104
PS
Sorafenib 100
RR 17 (11–26) (CR 1)




DOR ≥ 9 months 77











































PFS 3.0 (2.8–4.1) vs. 2.8
(1.6–3.0)






HR 0.718 (0.570–0.904) HR 0.781 (0.611–0.998)Child-PughA 99.6%
B 0.4%
BCLC stage
One-sided p = 0.0022 One-sided p = 0.0238B 20
C 80
Extrahepatic disease 70









































































Lee [47] Avelumab II 30
PS


































































































1. line RR 34.3 (95%
CI 23.3–46.6)
2. line RR 22.5 (95%
CI 15.4–31.0)
1. line 5.7 (95% CI
5.4–7.4)




1. line 74.7 (95% CI
62.5–83.5)
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Lee [56] Atezolizumab +
bevacizumab
Ib (GO30140, arm A)




RR 36 (CR 12)






A5–6 94 DOR Not reached










RR 20 vs. 17
DCR 67 vs. 49
DOR Not reached
(NE) vs. Not reached
(3.7–NE)
PFS 5.6 (3.6–7.4) vs. 3.4
(1.9–5.2)
Not reached (8.3–NE) vs.
Not reached (8.2–NE)
0 45 vs. 42
1 55 vs. 58
HBV+ 57 vs. 54
HCV+ 18 vs. 17
HR 0.55 (80% CI
0.40–0.74) p = 0.011
Child-Pugh
A 100 vs. 100
Extrahepatic disease or









RR 29.8 (24.8, 35.0) vs.
11.3 (6.9, 17.3)
CR 7.7 vs. 0.6
SD 44.2 vs. 43.4




6-months PFS 54.5% vs.
37.2%
12-month OS 67.2% vs.
54.6%
median OS 19.2 months
vs. 13.4 month (HR, 0.66;
95% CI, 0.52, 0.85;
p = 0.0009)






A5 72 vs. 73
A6 28 vs. 27
B7 0.3 vs. 0
Kudo [59] Avelumab +
axitinib
I b (VEGF Liver 100)
(preliminary data) 22
PS 0–1 No prior therapy RR 13.6 (2.9–34.9) NR NA (immature)Child-Pugh A
Bang [60] Durvalumab +
ramucirumab Ib 28
PS
1 prior regimen 93 RR 11
DCR 61
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Treatment Phase Number of Patients(Evaluable) Patient Characteristics
Previous Systemic











































Nivolumab 1 mg/kg +
ipilimumab 3 mg/kg
Q3W x 4→ nivolumab
240 mg Q2W
Nivolumab 3 mg/kg +
ipilimumab 1 mg/kg















HBV+ 28 All 15
HCV+ 22 Uninfected 30
Child-Pugh Infected 0





















84 9.5 (4.2–17.9) 11.3 (8.4–14.6)
104 9.6 (4.7–17.0) 11.7 (8.5–16.9)
69 7.2 (2.4–16.1) 17.1 (10.9–notreached)




10 (+ biliary cancer) Advanced At least one priorsystemic therapy
PR 20 PFS 7.8 (2.6–10.6) 15.9 (7.1–16.3)NR SD 40
PD-1/PD-L1 in combination with other drugs
Qin [68] Camrelizumab +
FOLFOX4 or GEMOX







PFS 5.5 NRDCR 79.4
DOR not reached (3.3–11.5 + months)


























SD 42 + ablation
RR 24
All patients
5 (95% CI 2.9–7.1)
All patients














RR 31.0 (95% CI
16.4–48.1) 4.6 (95% CI 2.3–8.4) 15.1 (95% CI 7.8–NE)Child-Pugh AHBV+ 64
DCR 58.3BCLC C 64
Preoperative; eligible for surgical resection
CTLA-4 and PD-1/PD-L1 combination therapy
Kaseb [71]

























CA, cryoablation; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; FOLFOX4, 5-flourouracil, leucovorin and oxaliplatin; GEMOX, gemcitabine and
oxaliplatin; HBV, Hepatitis B virus; HCV, Hepatitis C virus; NA, not available; NE, not estimable; NR, not reported; OS, overall survival; pCR, pathological complete response; PFS, progression free survival; PR,
partial response; PS, performance status; RFA, radiofrequency ablation; RR, response rate; SD, stable disease; TACE, chemoembolization; TTP, time to progression.
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Advanced, not amenable for resection or ablation
CTLA-4 inhibition









Nivolumab 48 83 25 21 10 15 6 0 0
2
Grade 5 0













371 vs. 372 - 22 vs. 49 - - - - - -
4 vs. 8
Sorafenib Grade 5 NR
Zhu [40]
(Keynote-224) Pembrolizumab 104 73 24 14 7 9 5 3
- 5
Grade 5 1








278 vs. 135 96 vs. 90 52 vs. 4619 vs. 5 (TRAE) 23 vs. 16 13 vs. 8 18 vs. 10 6 vs. 3 3 vs. 0 1 vs. 0
17 vs. 9
Grade 5 2.5 vs. 3.0
Qin [44] Camrelizumab(q2w or Q3w) 220 (217)
- -






(RCCEP 67) (RCCEP 0) Grade 5 0.9 (hepaticfailure 0.5)
Pishvaian [45] Cemiplimab 26 - - 23 8 - - - 8
NR
Grade 5 7.7
Wainberg [46] Durvalumab 40 80 20 23 8 - 5 - -
18
Grade 5 0
Lee [47] Avelumab 30 77 23
AST/ALT AST/ALT - - - - 7
23 13 Grade 5 0
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PD-1/PD-L1 inhibition in combination with antiangiogenic agents
Finn [51]
Pembrolizumab
+ lenvatinib 100 99
67
30 14 19 6 - -
18
(hypertension 17) Grade 5 3
Xu [52] Camrelizumab +apatinib
33 (+ gastric or esophageal junction
cancer; dose expansion phase)
- - 52 15 39 9 - -
9
Grade 5 0
Xu [53] Camrelizumab +apatinib 190 (190)
99.5 774







RCCEP 0.5) Grade 5 1.1
Jiao [55] Penpulimab +
anlotinib
40 (36) 94 10 36 - 29 - - -
7
Grade 5 0













20 vs. 5 5 vs. 14 (AEsi) 3 vs. 3(AEsi)-
5 vs. 9
(AEsi)- 0 vs. 0 0 vs. 0 0 vs. 0
2 vs. 1





336 vs. 165 98 vs. 98
56.51 vs. 55.1









12.2) Grade 5 4.6 vs. 5.8




- - - - - 0




23 Grade 5 0




25 18 7 4 - - 18
Grade 5 7














































































Durvalumab + tremelimumab 300 mg single dose























[66] Durvalumab + tremelimumab
10 (+ biliary
cancer) - - - - - - - - -
PD-1/PD-L1 in combination with other drugs
Qin [68] Camrelizumab + FOLFOX4 or GEMOX
34 (+ biliary
tract cancer)
- 85 - - - - - -
0
Grade 5 NR
PD-1/PD-L1 in combination with other treatment strategies
Lyu [69] Nivolumab/pembrolizumab→nivolumab/pembrolizumab + subtotal thermal ablation 50 82 - 20 (+ ALAT) 0 (+ ALAT) - - 0 0
8
Grade 5 1/50
Tai [70] Y90-radioembolization→Nivolumab 40 (36) - 11 - - - - - - -
Preoperative; eligible for surgical resection
CTLA-4 and PD-1/PD-L1 combination therapy
Kaseb [71] Nivolumab vs. Nivolumab + ipilimumab
13 vs. 14






AE, adverse event; RCCEP, reactive cutaneous capillary endothelial proliferation; TRAE, treatment-related adverse event. 1. All AEs; 2. All AEs ≥ grade 2; 3. Treatment emergent AEs.
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Table 4. Correlation between response and PD-L1 expression.






PD-L1 assessed by membrane expression on
tumor cells:
Positive (≥1%) (n = 11) RR 27%; negative (<1%)
(n = 33) RR 12%; p-value NR
Nivolumab 214 174
PD-L1 assessed by membrane expression on
tumor cells:
Positive (≥1%) (n = 34) RR 26%; negative (<1%)
(n = 140) RR 19%; p-value NR
Sangro [105]
(CheckMate 040) Nivolumab 262 PD-L1 195
PD-L1 assessed by membrane expression on
tumor cells:
Positive (≥1%) (n = 36) RR 28% (16–44); negative
(<1%) (n = 159) RR 16% (11–22); p-value NR
Positive (≥1%) (n = 36) median OS 28.1 months
(95% CI 18.2-NA); negative (<1%) (n = 159);
median OS 16.6 months (95% CI 14.2–20.2)
(p = 0.032)
Yau [39] (CheckMate 459)
Nivolumab
371 366
PD-L1 assessed by tumor positive score:
Sorafenib Positive (≥1%) (n = 71): RR 28%; negative (<1%)(n = 295) RR 12%; (p-value NR)
Zhu [40] (Keynote-224),
Kudo [41] Pembrolizumab 104 52
PD-L1 assessed by combined positive score
(CPS) (a measure of PD-L1 positive immune and
tumor cell number):
Positive (≥1%) (n = 22): RR 32%; negative (<1%)
(n = 30) RR 20%; p = 0.021
PD-L1 assessed by tumor positive score (TPS):
Positive (≥1%) (n = 7): RR 43%; negative (<1%)
(n = 45) RR 22%; p = 0.088
Feun [42] Pembrolizumab 29 10
Method for PD-L1 assessment NR:
Positive (level NR) (n = 4) RR 25%; negative
(level NR) (n = 6) RR 33%
Qin [44] Camrelizumab (q2w orQ3w) 220 30
PD-L1 assessed by tumor proportion score:
Positive (≥1%) (n = 11) RR 36%; negative (<1%)
(n = 19) RR 11% (p-value NR)
Lee [47] Avelumab 30 27
Four antibodies were investigated with different
evaluation methods used for each clone:
Expression of PD-L1 was not associated with
response
Xu [52] Camrelizumab + apatinib
43 (+ gastric or
esophageal junction
cancer)
18 (type of cancer
NR)39
PD-L1 assessed on circulating tumor cells (CTC):
High (≥20%) RR 48%; Low (<20%) RR 0%; p =
0.002; PFS significantly longer in patients with
high expression compared to low (HR 0.28;
p = 0.0002; OS not significantly different (HR
0.40; p = 0.601)
Xu [53] Camrelizumab + apatinib 190 54
PD-L1 assessed by tumor proportion score:
RR and PFS similar between positive (≥1%) and
negative (<1%) patients
Lee [56] Atezolizumab +
bevacizumab 104 86
PD-L1 assessed on tumor cells and
tumor-infiltrating immune cells:
Positive ≥ 1% (n = 61) RR 41%; ≥ 5% (n = 37) RR
46%; ≥ 10% (n = 30) RR 50%
Negative < 1% (n = 25) RR 28%; < 5% (n = 49) RR








PD-L1 assessed on tumor cells and
tumor-infiltrating immune cells:
Positive ≥ 1% (n = 62) PFS 5.6 months; ≥ 5%
(n = 24) PFS 4.1 months; ≥ 10% (n = 11) PFS 3.7
months
Negative < 1% (n = 33) PFS 5.7 months; < 5%
(n = 71) PFS 5.7 months; < 10% (n = 84) PFS 5.7
months (p-value NR)
Positive ≥ 1% (n = 62) PFS 2.1 months; ≥ 5%
(n = 24) PFS 1.9 months; ≥ 10% (n = 11) PFS 2.7
months
Negative < 1% (n = 33) PFS 4.0 months; < 5%
(n = 71) PFS 3.7; < 10% (n = 84) PFS 5.4 months
(p-values NR)
Bang [60] Durvalumab +
ramucirumab 28 26
PD-L1 assessed on tumor cells:
High (≥25%) (n = 11) RR 18% and SD 73%; low
(<25%) (n = 15) RR 0 and SD 47% (p-values NR)
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Table 4. Cont.










Method for PD-L1 assessment NR:
Positive (≥1%) (n = 10) RR 30%, OS 18.8 months;
negative (<1%) (n = 39) RR 31%, OS 22.2 months
Positive (≥1%) (n = 10) RR 30%, OS 10.2 months;
negative (<1%) (n = 38) RR 32%, OS 12.5 months
Positive (≥1%) (n = 8) RR 50%, OS NE; negative
(<1%) (n = 40) RR 28% OS 10.4 months
CTC, circulating tumor cells; NR, not reported, HR, hazard ratio; OS, overall survival; NA, not available; PFS, progression-free survival; RR,
response rate; SD, stable disease.
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inhibitors in advanced/metastatic hepatocellular carcinoma, Supplementary Table S2: Ongoing
studies with checkpoint inhibitors in locally advanced hepatocellular carcinoma, Supplementary
Table S3: Ongoing studies with checkpoint inhibitors in hepatocellular carcinoma in the preoperative
or adjuvant setting.
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